Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 273-282

  Mahdian, Reza ^a,c   Kokhaei, Parviz ^a,b   Najar, Hossein Motieian ^d   Derkow, Katja ^a   Choudhury, Aniruddha ^a   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dendritic cells; Immunotherapy; Melanoma; T cell; Tumor lysate

Indexed keywords

ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; TUMOR ANTIGEN;

ALLOGENEIC RESTRICTION; ARTICLE; CANCER IMMUNOTHERAPY; CELL LABELING; CELL LYSATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENDOCYTOSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEASUREMENT; MELANOMA CELL; MONOCYTE; PRIMED LYMPHOCYTE TYPING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DENDRITIC CELLS; HUMANS; ISOANTIGENS; K562 CELLS; LYMPHOCYTE ACTIVATION; MELANOMA; MONOCYTES; T-LYMPHOCYTES;

EID: 33646880439     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:273     Document Type: Article

References (30)

1. Mayordomo JI, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
2. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287.
3. Zitvogel L, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
4. Song W, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
5. Specht JM, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-1221.
6. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 46.
7. Gong J, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6279-6283.
8. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998; 9: 757-763.
9. Berard F, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192: 1535-1544.
10. Chang AE, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002; 8: 1021-1032.
11. Avila-Carino J, et al. EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. Int J Cancer 1994; 58: 678-685.
12. Feuerstein B, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15-29.
13. Coligan JE. Current protocols in immunology. Wiley: New York, 1991.
14. Kokhaei P, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17: 894-899.
15. Osterborg A, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459-2466.
16. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772-4780.
17. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001; 193: F5-9.
18. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000; 60: 3542-3549.
19. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
20. Mellstedt H, et al. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann NY Acad Sci 2000; 910: 254; discussion, 261.
21. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
22. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001; 61: 8105-8109.
23. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61: 2618-2624.
24. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487.
25. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002; 99: 3280-3285.
26. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96: 1857-1864.
27. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001; 91: 749-756.
28. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
29. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000; 356: 1163-1165.
30. Stift A, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003; 21: 135-142.